Cargando…
413. Intravenous and Tablet Formulation of Posaconazole in Antifungal Therapy and Prophylaxis: A Retrospective, Non-Interventional, Multicenter Analysis of Patients Treated in German Tertiary-Care Hospitals
BACKGROUND: Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs). The aim of this multicenter noninterventional study was to analyze treatment strategies and clinical effectiveness...
Autores principales: | Heimann, Sebastian M, Penack, Olaf, Heinz, Werner J, Rachow, Tobias, Egerer, Gerlinde, Kessel, Johanna, Löhnert, Annika, Vehreschild, Janne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255490/ http://dx.doi.org/10.1093/ofid/ofy210.424 |
Ejemplares similares
-
412. Clinical and Pharmacoeconomic Evaluation of Antifungal Prophylaxis With Continuous Micafungin Compared to Posaconazole With Micafungin Bridging in Patients Undergoing Allogeneic Stem Cell Transplantation: A 6-Year Cohort Analysis
por: Heimann, Sebastian M, et al.
Publicado: (2018) -
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia
por: Döring, M., et al.
Publicado: (2015) -
Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020) -
Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023) -
The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study
por: Özkocaman, Vildan, et al.
Publicado: (2018)